Teva Pharmaceutical Industries ADR (TEVA)

$30.64 -0.57 (-1.83%)
Market Cap 35.23B
Revenue (ttm) 17.26B
Net Income (ttm) 1.41B
EPS (ttm) N/A
PE Ratio 11.11
Forward PE 11.91
Profit Margin 8.18%
Debt to Equity Ratio 2.12
Volume 4,826,800
Avg Vol 6,285,980
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 22%
Beta 0.76
Analysts Strong Sell
Price Target $37.64

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
shoagh12
shoagh12 Apr. 27 at 1:59 PM
$TEVA 40$ end of the Week
0 · Reply
AirForce1000
AirForce1000 Apr. 27 at 12:55 AM
$TEVA LFG https://www.knicksnewyork.com
0 · Reply
AbovetheGreenLine
AbovetheGreenLine Apr. 22 at 7:20 PM
EXIT Teva Pharma. $TEVA if it is going to Close below $30.96. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr
0 · Reply
Quantumup
Quantumup Apr. 22 at 10:37 AM
Barclays🏁 $TRAX.X and said: We initiate coverage of First Tracks Biotherapeutics at Overweight with a $40 PT, in the wake of the spin from AnaptysBio (ANAB, OW). $ANAB $NVS $FBRX $TEVA RPRX EPRX Here's what else Barclays had to say in its First Tracks Biotherapeutics initiation report:
0 · Reply
Contrarian_Dan
Contrarian_Dan Apr. 22 at 12:35 AM
$TEVA This is easily a $50 print in the next 24 months.
0 · Reply
tkstockpicker
tkstockpicker Apr. 21 at 7:27 PM
$TEVA added
0 · Reply
thinkandpick
thinkandpick Apr. 21 at 2:55 PM
$SYNX $WIX $TEVA $SEDG $CYBR Israeli stocks. Dirt-cheap Israeli defense company Silynxcom (SYNX) announces another purchase order that also incorporates the “drone detection” headset feature: https://www.globenewswire.com/news-release/2026/04/21/3278082/0/en/silynxcom-secures-approximately-500-000-order-for-advanced-tactical-protective-systems-from-new-asian-military-customer.html With so many purchase orders that exceed $7 million over the last months, there is no question that SYNX's revenue in 2026 will be MUCH HIGHER than in 2025 and $SYNX will be profitable.
0 · Reply
Turbofueled
Turbofueled Apr. 21 at 1:33 PM
$LEXX Let it begin! 🔥🔥🔥🔥🔥🚀🚀🚀🚀 https://lexariabioscience.com/2026/04/21/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-industry-sales/ $NVO $LLY $TEVA
0 · Reply
TheDudeRooster
TheDudeRooster Apr. 20 at 6:44 PM
$TEVA Big Stanky
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 12:11 PM
$TEVA TURNING ON YOUR 38.88PT FILLER LONGS OK
0 · Reply
Latest News on TEVA
3 Catalysts That Could Send Teva Stock to $40 and Beyond

Sat, 18 Apr 2026 04:44:00 -0400 - 9 days ago

3 Catalysts That Could Send Teva Stock to $40 and Beyond

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 3.6% -- What GF Score of 54 Tells Investors

2026-04-17T22:36:00.000Z - 9 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 3.6% -- What GF Score of 54 Tells Investors

Notable ETF Inflow Detected - ACWX, SPOT, PDD, TEVA

2026-04-16T15:10:13.000Z - 11 days ago

Notable ETF Inflow Detected - ACWX, SPOT, PDD, TEVA

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Wed, 15 Apr 2026 08:00:00 -0400 - 12 days ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Tue, 14 Apr 2026 08:00:00 -0400 - 13 days ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

TEVA's Price Target Raised by B of A Securities, Maintains 'Buy' Rating | TEVA Stock News

2026-04-09T17:31:06.000Z - 17 days ago

TEVA's Price Target Raised by B of A Securities, Maintains 'Buy' Rating | TEVA Stock News

Teva Pharmaceutical Industries Ltd (TEVA) Trading 3.32% Higher on Apr 8

2026-04-08T17:09:37.000Z - 18 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Trading 3.32% Higher on Apr 8

Notable ETF Inflow Detected - ACWX, SPOT, TEVA, SUNB

2026-04-08T14:51:02.000Z - 19 days ago

Notable ETF Inflow Detected - ACWX, SPOT, TEVA, SUNB

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31

2026-03-31T18:09:12.000Z - 26 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31

Teva (TEVA) Advances with Biosimilar Application Review for Xolair

2026-03-30T22:32:54.000Z - 27 days ago

Teva (TEVA) Advances with Biosimilar Application Review for Xolair

FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar

2026-03-30T22:31:28.000Z - 27 days ago

FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar

Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30

2026-03-30T18:02:24.000Z - 27 days ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30

Notable ETF Outflow Detected - FNDF, MDT, ZIM, TEVA

2026-03-30T14:49:04.000Z - 4 weeks ago

Notable ETF Outflow Detected - FNDF, MDT, ZIM, TEVA

Teva Secures FDA Nod For PONLIMSI, Biosimilar Candidate To Xolair Applications Accepted By FDA & EMA

2026-03-30T13:29:13.000Z - 4 weeks ago

Teva Secures FDA Nod For PONLIMSI, Biosimilar Candidate To Xolair Applications Accepted By FDA & EMA

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Mon, 30 Mar 2026 08:00:00 -0400 - 4 weeks ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-03-19T23:06:08.000Z - 5 weeks ago

Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Teva Releases Q1 2026 Aide Memoire

Thu, 19 Mar 2026 16:30:00 -0400 - 5 weeks ago

Teva Releases Q1 2026 Aide Memoire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Thu, 19 Mar 2026 16:30:00 -0400 - 5 weeks ago

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript

2026-03-10T17:00:23.000Z - 6 weeks ago

Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 6 weeks ago

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:00 AM EDT - 7 weeks ago

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

The 3 Best Stocks to Invest $1,000 in Right Now

Fri, 06 Mar 2026 14:00:00 -0500 - 7 weeks ago

The 3 Best Stocks to Invest $1,000 in Right Now

Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's

2026-03-05T08:57:00.000Z - 7 weeks ago

Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

2026-03-04T18:47:00.000Z - 7 weeks ago

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

3 Generic Drug Stocks to Watch Despite Industry Headwinds

2026-03-04T14:42:00.000Z - 7 weeks ago

3 Generic Drug Stocks to Watch Despite Industry Headwinds

Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News

2026-03-04T14:04:23.000Z - 7 weeks ago

Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding

Wed, 04 Mar 2026 04:06:00 -0500 - 7 weeks ago

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding

Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug

2026-03-04T06:11:03.000Z - 7 weeks ago

Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug

Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development

2026-03-03T22:58:10.000Z - 7 weeks ago

Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development

Blackstone (BX) Commits $400M to Teva for Duvakitug Development

2026-03-03T22:28:17.000Z - 7 weeks ago

Blackstone (BX) Commits $400M to Teva for Duvakitug Development

Teva Pharmaceutical Industries Ltd (TEVA) Shares Gap Down to $32.22 on Mar 3

2026-03-03T16:10:02.000Z - 7 weeks ago

Teva Pharmaceutical Industries Ltd (TEVA) Shares Gap Down to $32.22 on Mar 3

Eliyahu Kalif Sells 345,810 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

2026-03-02T22:03:41.000Z - 7 weeks ago

Eliyahu Kalif Sells 345,810 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

The Best Healthcare Stock to Invest $1,000 in Right Now

Mon, 02 Mar 2026 15:00:00 -0500 - 7 weeks ago

The Best Healthcare Stock to Invest $1,000 in Right Now

What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd?

2026-03-02T13:00:31.000Z - 2 months ago

What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd?

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole

Fri, 27 Feb 2026 18:22:00 -0500 - 2 months ago

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole

Teva to Present at the Upcoming Investor Conferences in March

Feb 24, 2026, 4:30 PM EST - 2 months ago

Teva to Present at the Upcoming Investor Conferences in March

TEVA

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

2026-02-23T13:48:16.000Z - 2 months ago

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Teva (TEVA) Advances Schizophrenia Treatment with FDA Application

2026-02-21T14:55:21.000Z - 2 months ago

Teva (TEVA) Advances Schizophrenia Treatment with FDA Application

FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment

2026-02-21T06:31:14.000Z - 2 months ago

FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment

Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application

2026-02-20T20:25:33.000Z - 2 months ago

Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Feb 20, 2026, 2:43 PM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

TEVA

Price Over Earnings Overview: Teva Pharmaceutical Indus

2026-02-20T15:00:36.000Z - 2 months ago

Price Over Earnings Overview: Teva Pharmaceutical Indus

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

2026-02-19T16:48:26.000Z - 2 months ago

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Teva Pharmaceutical Industries Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 2 months ago

Teva Pharmaceutical Industries Transcript: Study result

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Feb 17, 2026, 7:04 AM EST - 2 months ago

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

TEVA

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 2 months ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

TEVA

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 9:30 AM EST - 2 months ago

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

Jan 28, 2026, 12:22 PM EST - 3 months ago

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook

TEVA

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Jan 28, 2026, 8:00 AM EST - 3 months ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:31 AM EST - 3 months ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

TEVA

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 28, 2026, 7:00 AM EST - 3 months ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 27, 2026, 8:00 AM EST - 3 months ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 5:02 PM EST - 3 months ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Jan 12, 2026, 12:26 PM EST - 3 months ago

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

RPRX

Why Investors Are So Optimistic on Teva

Jan 12, 2026, 10:46 AM EST - 3 months ago

Why Investors Are So Optimistic on Teva

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 6:00 PM EST - 3 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:00 PM EST - 3 months ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:30 PM EST - 3 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Top 2 Health Care Stocks That May Crash In Q1

Jan 2, 2026, 8:58 AM EST - 4 months ago

Top 2 Health Care Stocks That May Crash In Q1

EXAS

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 24, 2025, 8:36 AM EST - 4 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 19, 2025, 3:40 AM EST - 4 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 9, 2025, 8:00 AM EST - 4 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 25, 2025, 8:10 AM EST - 5 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 21, 2025, 4:30 PM EST - 5 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Teva seeks startups to help solve global pharmaceutical challenges

Nov 19, 2025, 8:07 AM EST - 5 months ago

Teva seeks startups to help solve global pharmaceutical challenges

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 7, 2025, 6:00 PM EST - 6 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:02 PM EST - 6 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Nov 5, 2025, 11:30 AM EST - 6 months ago

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 9:14 AM EST - 6 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Nov 5, 2025, 7:44 AM EST - 6 months ago

Teva Pharm third-quarter profit tops estimates as branded drugs gain

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Nov 5, 2025, 7:00 AM EST - 6 months ago

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 31, 2025, 4:30 PM EDT - 6 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Blood pressure medicine recalled over high levels of cancer-causing chemical

Oct 30, 2025, 11:45 AM EDT - 6 months ago

Blood pressure medicine recalled over high levels of cancer-causing chemical

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 20, 2025, 4:30 PM EDT - 6 months ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 10, 2025, 3:00 PM EDT - 7 months ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 7 months ago

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 4:30 PM EDT - 7 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 20, 2025, 10:15 PM EDT - 7 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 16, 2025, 4:30 PM EDT - 7 months ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Colorado must face Teva's lawsuit over free allergy pen law

Sep 5, 2025, 3:57 PM EDT - 8 months ago

Colorado must face Teva's lawsuit over free allergy pen law

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Sep 2, 2025, 4:30 PM EDT - 8 months ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 9:17 AM EDT - 8 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 19, 2025, 9:00 AM EDT - 8 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

US FDA approves Teva's Ajovy for migraine prevention in children

Aug 5, 2025, 6:16 PM EDT - 9 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Teva CEO: Our supply chain puts us in a strong position

Jul 30, 2025, 12:40 PM EDT - 9 months ago

Teva CEO: Our supply chain puts us in a strong position

Teva Pharm Q2 profit beats estimates as branded drugs gain

Jul 30, 2025, 7:21 AM EDT - 9 months ago

Teva Pharm Q2 profit beats estimates as branded drugs gain

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Jul 29, 2025, 2:44 PM EDT - 9 months ago

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Releases Q2 2025 Aide Memoire

Jun 26, 2025, 4:30 PM EDT - 10 months ago

Teva Releases Q2 2025 Aide Memoire

shoagh12
shoagh12 Apr. 27 at 1:59 PM
$TEVA 40$ end of the Week
0 · Reply
AirForce1000
AirForce1000 Apr. 27 at 12:55 AM
$TEVA LFG https://www.knicksnewyork.com
0 · Reply
AbovetheGreenLine
AbovetheGreenLine Apr. 22 at 7:20 PM
EXIT Teva Pharma. $TEVA if it is going to Close below $30.96. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr
0 · Reply
Quantumup
Quantumup Apr. 22 at 10:37 AM
Barclays🏁 $TRAX.X and said: We initiate coverage of First Tracks Biotherapeutics at Overweight with a $40 PT, in the wake of the spin from AnaptysBio (ANAB, OW). $ANAB $NVS $FBRX $TEVA RPRX EPRX Here's what else Barclays had to say in its First Tracks Biotherapeutics initiation report:
0 · Reply
Contrarian_Dan
Contrarian_Dan Apr. 22 at 12:35 AM
$TEVA This is easily a $50 print in the next 24 months.
0 · Reply
tkstockpicker
tkstockpicker Apr. 21 at 7:27 PM
$TEVA added
0 · Reply
thinkandpick
thinkandpick Apr. 21 at 2:55 PM
$SYNX $WIX $TEVA $SEDG $CYBR Israeli stocks. Dirt-cheap Israeli defense company Silynxcom (SYNX) announces another purchase order that also incorporates the “drone detection” headset feature: https://www.globenewswire.com/news-release/2026/04/21/3278082/0/en/silynxcom-secures-approximately-500-000-order-for-advanced-tactical-protective-systems-from-new-asian-military-customer.html With so many purchase orders that exceed $7 million over the last months, there is no question that SYNX's revenue in 2026 will be MUCH HIGHER than in 2025 and $SYNX will be profitable.
0 · Reply
Turbofueled
Turbofueled Apr. 21 at 1:33 PM
$LEXX Let it begin! 🔥🔥🔥🔥🔥🚀🚀🚀🚀 https://lexariabioscience.com/2026/04/21/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-industry-sales/ $NVO $LLY $TEVA
0 · Reply
TheDudeRooster
TheDudeRooster Apr. 20 at 6:44 PM
$TEVA Big Stanky
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 12:11 PM
$TEVA TURNING ON YOUR 38.88PT FILLER LONGS OK
0 · Reply
DeepRoots42
DeepRoots42 Apr. 18 at 11:01 PM
$DJT $PLTR $FOXA $WBD $TEVA https://www.facebook.com/share/r/1CX1kYXryf/?mibextid=wwXIfr
0 · Reply
S2K_TP
S2K_TP Apr. 18 at 1:39 PM
$TEVA 40 break on watch next month 👀🚨
0 · Reply
BerniceGarza1
BerniceGarza1 Apr. 18 at 1:35 PM
$TEVA Looking good out there today. Keep the focus: discipline over emotion, process over outcome. Trade with a plan, trade with patience. 💹 Stay informed and catch the opportunities! @BerniceGarza1
0 · Reply
MESSPAC
MESSPAC Apr. 18 at 1:27 PM
$TEVA hey that's the brand of my anti-psychotic script
0 · Reply
User32548888
User32548888 Apr. 18 at 12:51 PM
$TEVA #AI
0 · Reply
SdotRayborn
SdotRayborn Apr. 18 at 12:30 PM
$TEVA trending again but why 🤔 lmao
1 · Reply
LewisDaKat
LewisDaKat Apr. 18 at 11:30 AM
$TEVA 3 Catalysts That Could Send Teva Stock to $40 and Beyond https://marketwirenews.com/stock/teva/news/3-catalysts-that-could-send-teva-stock-to-40-and-bey-8550246312823770.html?utm_source=stocktwits
0 · Reply
thinkandpick
thinkandpick Apr. 18 at 6:56 AM
$TEVA $WIX $MBLY $GILT $CYBR Israeli stocks. Israeli Elbit Systems (ESLT): Execution Remains Strong But Expectations Run High, comprehensive article: https://seekingalpha.com/article/4883505-elbit-systems-stock-q4-execution-remains-strong-but-expectations-run-high
0 · Reply
shepsale
shepsale Apr. 17 at 3:39 PM
$TEVA any news?
1 · Reply
SdotRayborn
SdotRayborn Apr. 17 at 3:27 PM
$TEVA no volume for months up or down
0 · Reply
scotttrader213
scotttrader213 Apr. 16 at 2:17 AM
$VTRS $TEVA for years $TEVA didn’t move. $VTRS is reminding me of $TEVA and now look at $TEVA. $VTRS long
0 · Reply
prismmarketview
prismmarketview Apr. 15 at 4:06 PM
$TEVA launched “Home Ground Schizophrenia Community,” a free online hub co‑built with patients, care partners and advocacy groups. It centralizes symptom‑tracking tools, emotional wellness content, independence guides and community events to tackle social isolation head‑on. #TevaPharma #HomeGround #SchizophreniaSupport https://prismmarketview.com/teva-launches-home-ground-online-hub-for-schizophrenia-support/
0 · Reply